Curious to see your top suppliers emissions?
Book a demo for a pilot project
Book a demo for a pilot project
Icon plc, headquartered in Ireland (IE), is a leading player in the research and development services industry, specifically within the realm of clinical research. Founded in 1990, Icon has established itself as a trusted partner for pharmaceutical, biotechnology, and medical device companies, offering a comprehensive suite of services that span the entire drug development lifecycle.
With a strong presence in North America, Europe, and Asia, Icon excels in providing innovative solutions that enhance clinical trial efficiency and patient engagement. Their core offerings include clinical trial management, regulatory consulting, and data analytics, all designed to streamline the development process and improve outcomes. Icon's commitment to quality and innovation has positioned it as a market leader, recognised for its ability to adapt to the evolving needs of the healthcare sector.
+48 vs industry average
Icon’s score of 80 is higher than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Research Services has below-average carbon intensity
The Research Services industry has reduced its overall emissions by 19% since 2018
Scope 3 accounts for ••• of total emissions.
ICON's 2024 carbon emissions totalled approximately 361.8 million kg CO2e. This figure comprises approximately 2.4 million kg CO2e from Scope 1 emissions and approximately 2.5 million kg CO2e from Scope 2 (market-based). Scope 3 emissions were the largest contributor, amounting to approximately 357 million kg CO2e, with purchased goods and services being a significant component.
In 2023, ICON reported total emissions of approximately 365.7 million kg CO2e, with Scope 1 at approximately 3 million kg CO2e, Scope 2 (market-based) at approximately 5.2 million kg CO2e, and Scope 3 at approximately 357.6 million kg CO2e.
ICON has set ambitious climate commitments. The company aims for a 61.2% absolute reduction in Scope 1 and 2 GHG emissions by FY2028, using FY2019 as a baseline. Further, ICON is committed to achieving a 90.0% absolute reduction in Scope 1 and 2 GHG emissions by FY2050 from the same FY2019 baseline. For Scope 3 emissions, ICON has set a near-term target of a 20.0% absolute reduction by FY2028 from a FY2022 baseline, and a long-term goal of a 90.0% absolute reduction by FY2050 from the FY2022 baseline. ICON has committed to reaching net-zero GHG emissions across its value chain by FY2050, a commitment validated by the Science Based Targets initiative (SBTi).
Access structured emission data, company specific factors and auditable source documents
2028
61.2% reduction in Scope 2
ICON plc commits to reduce absolute scope 2 GHG emissions 61.2% by FY2028 from a FY2019 base year.
2028
20% reduction in scope 3 total
ICON plc also commits to reduce absolute scope 3 GHG emissions 20.0% by FY2028 from a FY2022 base year.
2028
61.2% reduction in Scope 1
ICON plc commits to reduce absolute scope 1 GHG emissions 61.2% by FY2028 from a FY2019 base year.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
See all scope 3 categories
Already have an account? Sign in now


Common questions about Icon’s sustainability data and climate commitments
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more